The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2017
Filed:
Oct. 10, 2013
Amgen Inc., Thousand Oaks, CA (US);
Richard T. Lewis, Houston, TX (US);
Jennifer R. Allen, Newbury Park, CA (US);
Yuan Cheng, Newbury Park, CA (US);
Deborah Choquette, Medford, MA (US);
Oleg Epstein, Belmont, MA (US);
Angel Guzman-Perez, Belmont, MA (US);
Paul E. Harrington, Camarillo, CA (US);
Zihao Hua, Andover, MA (US);
Randall W. Hungate, Longmont, CA (US);
Jason Brooks Human, Boston, MA (US);
Ted Judd, Granada Hills, CA (US);
Qingyian Liu, Camarillo, CA (US);
Patricia Lopez, Woodland Hills, CA (US);
Ana Elena Minatti, Santa Monica, CA (US);
Philip Olivieri, Charlestown, MA (US);
Karina Romero, Burlington, MA (US);
Shannon Rumfelt, Camarillo, CA (US);
Robert M. Rzasa, Ventura, CA (US);
Laurie Schenkel, Boston, MA (US);
John Stellwagen, Beverly, MA (US);
Ryan White, Somerville, MA (US);
Qiufen Xue, Newbury Park, CA (US);
Xiao Mei Zheng, Natick, MA (US);
Wenge Zhong, Thousand Oaks, CA (US);
Amgen, Inc., Thousand Oaks, CA (US);
Abstract
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, A, A, A, R, R, R, Rand n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.